pirfenidone has been researched along with Carcinoma, Renal Cell in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chai, D; Guo, Z; Han, L; Huang, N; Li, H; Li, J; Li, L; Lv, Y; Wang, G; Xu, D; Zheng, J; Zheng, W; Zhou, X | 1 |
1 other study(ies) available for pirfenidone and Carcinoma, Renal Cell
| Article | Year |
|---|---|
The Anti-fibrosis drug Pirfenidone modifies the immunosuppressive tumor microenvironment and prevents the progression of renal cell carcinoma by inhibiting tumor autocrine TGF-β.
Topics: Animals; Carcinoma, Renal Cell; Epithelial-Mesenchymal Transition; Female; Fibrosis; Humans; Kidney Neoplasms; Male; Mice; Pyridones; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Microenvironment | 2022 |